Higgsfield raised a $400M Series B at a $5.4B valuation on $700M of annualized revenue — the fastest-growing proof that AI video finally has a real business model.
Databricks planned to raise $1 billion. Investors offered $15 billion. It took $5 billion at a $190 billion valuation — on a $7 billion run-rate growing 80% a year.
Google cut Gemini 3.7 Flash to $0.75/$3.75 per million tokens — a 50% intro discount aimed straight at Claude and GPT, with the price snapping back Jan 1, 2027.
OpenAI-backed Thrive Holdings raised $2B at a $12B valuation to buy accounting and IT firms and rewire them with AI.
Lenovo posted a record $26.94B quarter, up 43% on booming AI server demand — but a $1.69B non-cash warrant charge flipped it to a $609M reported loss.
Higgsfield raised a $400M Series B at a $5.4B valuation on $700M of annualized revenue — the fastest-growing proof that AI video finally has a real business model.
🔥 Gigabyte Just Dropped a $400 WOLED Gaming Monitor and It Changes Everything...
The AI chip company Cerebras Systems — the most prominent challenger to Nvidia's GPU empire — hit the Nasdaq on Thursday under the ticker CBRS and...
> In 2025, startups discovered AI. In 2026, the winners figured out which tools to use and when. Here's the stack the smartest founders are runni...
Bending Spoons is buying Airtable for $1.285 billion in all cash — about 89% below the productivity startup's $11.7B pandemic-era peak, and its first deal since going public.
Bristol Myers Squibb's Zenbexus is the first CELMoD approved for multiple myeloma — cleared on a doubled deep-remission rate (41% vs 21%) and priced at $29,500 a cycle.
Jazz Pharmaceuticals is paying $820M upfront — up to $1.32B — for Actio Biosciences and its Phase 1 KCNT1 epilepsy drug, aimed at just ~2,500 U.S. patients.
After two rejections, Replimune's tumor-injected virus Tudriqev won accelerated FDA approval on August 6 — a 24.2% response rate in melanoma that had beaten standard immunotherapy.
